التفاصيل البيبلوغرافية
| العنوان: |
Three decades of glucose‐lowering therapy in patients at high cardiovascular risk — A real‐world analysis. |
| المؤلفون: |
Neyer, Magdalena1,2 (AUTHOR), Vogel, Johannes B.1,2 (AUTHOR), Elsner, Pascal1,2 (AUTHOR), Kuehrer, Heike2 (AUTHOR), Saely, Christoph H.1,2,3 (AUTHOR), Muendlein, Axel2 (AUTHOR), Vonbank, Alexander1,2,3 (AUTHOR), Mader, Arthur2,3 (AUTHOR), Festa, Andreas1,2 (AUTHOR), Drexel, Heinz1,2,4,5 (AUTHOR), Leiherer, Andreas1,2,6 (AUTHOR) andreas.leiherer@vivit.at |
| المصدر: |
Diabetes, Obesity & Metabolism. Feb2025, Vol. 27 Issue 2, p835-844. 10p. |
| مصطلحات موضوعية: |
*TYPE 2 diabetes, *COMBINATION drug therapy, *CORONARY angiography, *CARDIOVASCULAR agents, *SODIUM-glucose cotransporter 2 inhibitors |
| مستخلص: |
Aim: Over recent years, therapy options and strategies for type 2 diabetes mellitus (T2DM) have developed substantially. This study investigated glucose‐lowering treatment in patients with high cardiovascular risk over three decades. Materials and Methods: A total of 2158 patients undergoing elective coronary angiography at a tertiary care hospital in Europe were included in three sequential observational studies (OS): OS1 (1999–2000; n = 672), OS2 (2005–2008; n = 1005) and OS3 (2022–2023; n = 481). Sociodemographic data, patient‐reported medication, medical histories and blood samples were analysed. Results: A clear trend towards more complex glucose‐lowering therapies was found. A wider array of glucose‐lowering drugs was used over time (OS1: 11; OS2: 21; OS3: 25) and the number of different drugs used in combination therapy in a single patient increased to a maximum of five in OS3. Furthermore, substantial differences in applied medication regimens were observed: Sodium‐glucose cotransporter‐2 inhibitors were the most frequently reported substance class (34.0% of total reported glucose‐lowering drugs) in OS3, whilst metformin remained a key component (OS1: 33.9%; OS2: 41.8%; OS3: 32.0%). Other drug classes like sulfonylureas were largely replaced. A total of 69.2% of patients in OS3 achieved an HbA1c level of < 7% (vs. OS1: 51.9%, OS2: 54.7%; ptrend < 0.001). Over 25% of patients with T2DM were newly diagnosed at admission (OS1: 43.8%, OS2: 29.7%, OS3: 27.2%; ptrend < 0.001) and had therefore no diabetes‐related medication. Conclusion: These real‐world data emphasize a marked shift in T2DM treatment towards novel substance classes. However, the use of incretin mimetics remained low. Significantly more patients reached HbA1c targets in the most recent cohort. [ABSTRACT FROM AUTHOR] |
| قاعدة البيانات: |
Academic Search Index |